Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 1270 Published: May 31, 2022 Report Code: GDGMDHC22156IDB

The Human Immunodeficiency Virus Pipeline market research report provides a comprehensive overview on the therapeutics under development for Human Immunodeficiency Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus and features dormant and discontinued projects.

Key Targets in the Human Immunodeficiency Virus Pipeline Drugs Market

In the HIV pipeline drugs market the key targets are Reverse Transcriptase, Surface Protein gp12, Gag, HIV 1 Integrase, Glycoprotein 41, T Cell Surface Glycoprotein CD4, HIV 1 Retropepsin, P27, Pol Polyprotein, Capsid Protein, and Glycoprotein 140.

Human Immunodeficiency Virus Pipeline Drugs Market, by Targets

Human Immunodeficiency Virus Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Human Immunodeficiency Virus Pipeline Drugs Market

Reverse Transcriptase Inhibitor has the highest number of pipeline products followed by Surface Protein gp12 Inhibitor, HIV 1 Integrase Inhibitor, Glycoprotein 41 Inhibitor, T Cell Surface Glycoprotein CD4 Inhibitor, HIV 1 Retropepsin Inhibitor, Capsid Protein Inhibitor, HIV Integrase Inhibitor, C-C Chemokine Receptor Type 5 Antagonist, and Gag Inhibitor.

Human Immunodeficiency Virus Pipeline Drugs Market, by MoA

Human Immunodeficiency Virus Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the HIV pipeline drugs market are Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Topical, Vaginal, Intradermal, Rectal, and Nasal. Oral has the maximum number of pipeline products.

Human Immunodeficiency Virus Pipeline Drugs Market Analysis, by RoA

Human Immunodeficiency Virus Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Human Immunodeficiency Virus Pipeline Drugs Market

The key molecule types in the HIV pipeline drugs market are Small Molecule, Monoclonal Antibody, Subunit Vaccine, Recombinant Vector Vaccine, Gene-Modified Cell Therapy, Synthetic Peptide, DNA Vaccine, Vaccine, Cell Therapy, and mRNA Vaccine.

Human Immunodeficiency Virus Pipeline Drugs Market, by Molecule Type

Human Immunodeficiency Virus Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Human Immunodeficiency Virus Pipeline Drugs Market

The major companies in the HIV pipeline drugs market are Gilead Sciences Inc, ViiV Healthcare UK Ltd, Merck & Co Inc, Viriom Inc, Aphios Corp, Enochian Biosciences Inc, Statera Biopharma Inc, Johnson & Johnson, OyaGen Inc, and TaiMed Biologics Inc.

Human Immunodeficiency Virus Pipeline Drugs Market, by Major Companies

Human Immunodeficiency Virus Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Overview

Key Targets Reverse Transcriptase, Surface Protein gp12, Gag, HIV 1 Integrase, Glycoprotein 41, T Cell Surface Glycoprotein CD4, HIV 1 Retropepsin, P27, Pol Polyprotein, Capsid Protein, and Glycoprotein 140
Key Mechanisms of action Reverse Transcriptase Inhibitor, Surface Protein gp12 Inhibitor, HIV 1 Integrase Inhibitor, Glycoprotein 41 Inhibitor, T Cell Surface Glycoprotein CD4 Inhibitor, HIV 1 Retropepsin Inhibitor, Capsid Protein Inhibitor, HIV Integrase Inhibitor, C-C Chemokine Receptor Type 5 Antagonist, and Gag Inhibitor
Key Routes of Administration Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Topical, Vaginal, Intradermal, Rectal, and Nasal
Key molecule types Small Molecule, Monoclonal Antibody, Subunit Vaccine, Recombinant Vector Vaccine, Gene-Modified Cell Therapy, Synthetic Peptide, DNA Vaccine, Vaccine, Cell Therapy, and mRNA Vaccine
Major companies Gilead Sciences Inc, ViiV Healthcare UK Ltd, Merck & Co Inc, Viriom Inc, Aphios Corp, Enochian Biosciences Inc, Statera Biopharma Inc, Johnson & Johnson, OyaGen Inc, and TaiMed Biologics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Human Immunodeficiency Virus

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • 2A Pharma AB

    AbbVie Inc

    Abivax SA

    Acceleromics SL

    Actinobac Biomed Inc

    Adare Pharma Solutions

    Advanced Gene and Cell Technologies

    Aelix Therapeutics SL

    AiCuris Anti-infective Cures AG

    AIM ImmunoTech Inc

    AlbaJuna Therapeutics

    Alphamab Oncology

    AlphaVax Inc

    American Gene Technologies International Inc

    Amgen Inc

    Antion Biosciences SA

    Aphios Corp

    Apimeds Inc

    Ascletis Pharma Inc

    AUM LifeTech Inc

    Auro Vaccines LLC

    Autonomous Therapeutics Inc

    Avixgen Inc

    B Cell Design SAS

    Bionor Holding AS

    BioNTech SE

    Biosantech SA

    Biotron Ltd

    Bolder Biotechnology Inc

    Brandenburg Antiinfektiva GmbH

    Brii Biosciences Ltd

    Bristol-Myers Squibb Co

    BryoLogyx Inc

    Bukwang Pharmaceutical Co Ltd

    Celdara Medical LLC

    Celldex Therapeutics Inc

    Centivax Inc

    Chiesi Farmaceutici SpA

    Cidara Therapeutics Inc

    Clover Biopharmaceuticals Ltd

    Cocrystal Pharma Inc

    Codiak BioSciences Inc

    Collaborations Pharmaceuticals Inc

    Consegna Pharma Inc

    ConserV Bioscience Ltd

    CSL Ltd

    Curevac NV

    Cytodyn Inc

    CytRx Corp

    Dewpoint Therapeutics Inc

    DFH Pharma Inc

    Diaccurate

    E-Vaccines Inc

    Emmune Inc

    Enochian Biosciences Inc

    Enzo Biochem Inc

    Enzolytics Inc

    EpitoGenesis Inc

    EpiVax Inc

    eTheRNA Immunotherapies NV

    Evotec SE

    Exavir Therapeutics Inc

    Excision BioTherapeutics Inc

    ExQor Technologies Inc

    Fox Chase Chemical Diversity Center Inc

    Frontier Biotechnologies Inc

    FUJIFILM Toyama Chemical Co Ltd

    GB Sciences Inc

    GeneCure Biotechnologies LLC

    Genetic Immunity Inc

    GeoVax Labs Inc

    Gilead Sciences Inc

    Globeimmune Inc

    Greffex Inc

    Gritstone Bio Inc

    GT Biopharma Inc

    Guangzhou Bio-gene Technology Co Ltd

    HDT Bio Corp

    Helocyte Biosciences Inc

    Hepion Pharmaceuticals Inc

    Hetero Drugs Ltd

    Hoverink Biotechnologies Inc

    ID Pharma Co Ltd

    IGXBio Inc

    Immune Modulation Inc

    Immune Response BioPharma Inc

    ImmunityBio Inc

    Immuno Cure BioTech Ltd

    Immunocore Limited

    Immunologik GmbH

    Indaptus Therapeutics Inc

    Innovare R & D SA De CV

    Inovio Pharmaceuticals Inc

    Intarcia Therapeutics Inc

    Intrucept Biomedicine LLC (Inactive)

    InvVax Inc

    ISR Immune System Regulation Holding AB

    Ithax Pharmaceuticals Inc

    Jericho Sciences LLC

    Jiangsu Aidea Pharmaceutical Co Ltd

    Jiangsu Hengrui Medicine Co Ltd

    Johnson & Johnson

    Kainos Medicine Inc

    Kanglin Biotech Hangzhou Co Ltd

    Karyopharm Therapeutics Inc

    Lauren Sciences LLC

    Legend Biotech Corp

    Longevity Biotech Inc

    Luckwel Pharmaceuticals Inc

    Lyndra Therapeutics Inc.

    MacroGenics Inc

    Mapp Biopharmaceutical Inc

    MarPam Pharma LLC

    Merck & Co Inc

    METiS Pharmaceuticals

    Miltenyi Biotec BV & Co KG

    Minka Therapeutics SA

    Moderna Inc

    Molecular Express Inc

    Moleculin Biotech Inc

    Mologen AG

    Mutabilis SA

    Mycenax Biotech Inc

    Mymetics Corp

    NanoViricides Inc

    Navigen Inc

    NeED Pharma srl

    Neuraxpharm France SAS

    New World Laboratories Inc

    NovalGen Ltd

    Novartis AG

    Novodux

    Omeros Corp

    Oncotelic Inc

    Oncovir Inc

    OncXerna Therapeutics Inc

    Oneness Biotech Co Ltd

    Orion Biotechnology Canada Ltd

    Osel Inc

    OyaGen Inc

    Palisades Therapeutics

    Pepscan Therapeutics BV

    Pharmasyntez

    Pharmsynthez

    Phoenix Biotechnology Inc

    PlantForm Corp

    Prosetta Biosciences Inc

    Protheragen Inc

    PROVIREX Genome Editing Therapies GmbH

    Qura Therapeutics LLC

    Recombio SL

    ReiThera Srl

    Repair Biotechnologies Inc

    Replikins Ltd

    Resverlogix Corp

    RetroVirox Inc

    Rodos BioTarget GmbH

    Samjin Pharm Co Ltd

    Sangamo Therapeutics Inc

    Satellos Bioscience Inc

    Savoy Pharmaceuticals Inc

    Seagen Inc

    Secura Bio Inc

    Serum Institute of India Pvt Ltd

    Shanghai De Novo Pharmatech Co Ltd

    Shanghai Pharmaceutical Group Co Ltd

    Shanghai Record Pharmaceuticals Co Ltd

    Shanxi Kangbao Biological Product Co Ltd

    Shenzhen Chipscreen Biosciences Co Ltd

    Shionogi & Co Ltd

    SignalRx Pharmaceuticals Inc

    Sirga Advanced Biopharma Inc

    ST Pharm Co Ltd

    Staidson BioPharma Inc

    Starpharma Holdings Ltd

    Statera Biopharma Inc

    Sumagen Co Ltd

    Sunomix Therapeutics

    Susavion Biosciences Inc

    Taiga Biotechnologies Inc

    TaiMed Biologics Inc

    Takara Bio Inc

    TechnoVax Inc

    Tetranov International Inc

    Tevogen Bio Inc

    TheraJect Inc

    Theratechnologies Inc

    Theravectys SA

    Transgene Biotek Ltd

    Transposon Therapeutics Inc

    TVAX Biomedical Inc

    United Biomedical Inc

    Uvax Bio LLC

    Vault Pharma Inc

    VG Life Sciences Inc

    Vichem Chemie Research Ltd

    viIMMUNE

    ViiV Healthcare UK Ltd

    Vir Biotechnology Inc

    Viramatix Sdn Bhd

    Viravaxx AG

    Viriom Inc

    ViroStatics SRL

    Winsantor Inc

    Wuhan Bio-Raid Biotechnology Co Ltd

    Xi’An Yufan Biotechnology Co Ltd

    Xyphos Biosciences Inc

    Yaso Therapeutics Inc

    Yisheng Biopharma Co Ltd

    Zata Pharmaceuticals Inc

    Zion Medical

    Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Overview

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Companies Involved in Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Drug Profiles

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, 2022

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.